SANGAMO THERAPEUTICS, INCSGMO

時価総額
$1.4億
PER
2011年
12月31日
2012年
12月31日
2013年
12月31日
2014年
12月31日
2015年
12月31日
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
2023年
12月31日
Net loss--------69-95-121-178-192-258
Depreciation and amortization111111124691215
Goodwill and Intangible Asset Impairment------------89
(Accretion of discount) amortization of premium on marketable securities----1-1-01651-312
Impairment of long-lived assets------------66
Amortization and other changes in operating lease right-of-use assets---------6-8-8-8-
Depreciation and amortization111111124691215
Stock-based compensation856912159151926333227
(Accretion of discount) amortization of premium on marketable securities----1-1-01651-312
Gain on free shares--------000--
Amortization in operating lease right-of-use assets------------7
Net (gain) loss on disposal of property and equipment--0-----0--0-00--
Deferred income tax benefit-----6-0-------6
Adjustment of CIRM award liability related to termination of the grant----------6--
Stock-based compensation856912159151926333227
Other------0-0------1
Adjustment of CIRM award liability related to termination of the grant----------6--
Interest receivable-0-000-0-00000-10-0
Accounts receivable13-17-82-2132-321-2-3
Prepaid expenses and other assets0-000-011371075-6
Accounts payable and other accrued liabilities---4-1-23-6-411-8136
Accrued compensation and employee benefits011-0-00334701-13
Deferred revenues-------99-36217-84-91-161
Lease liabilities------------2-
Lease liabilities-------------5
Other non-current liabilities-------2411-0-0
Net cash used in by operating activities-26-8-19----37-144170-233-224-225
Purchases of marketable securities1139111922825821925245144457133827760
Maturities of marketable securities---128338237179392405315603355-
Maturities of marketable securities------------215
Sales of marketable securities8310351-------7220
Purchases of property and equipment1101214432115232021
Purchase of additional Sangamo France shares--------010--
Net cash provided by investing activities-2011-68-----178-60-27224859154
At-The-Market Offering----------278515
Employee Stock----------321
Employee Stock----------321
Proceeds from issuance of common stock52291371171622---
Taxes paid related to net share settlement of equity awards--25211001322
Proceeds from exercise of stock options--------4960-
Net cash provided by financing activities52276----232142153338515
Effect of exchange rate changes on cash and cash equivalents, and restricted cash--------0-0-011
Net (decrease) increase in cash, cash equivalents, and restricted cash-------91-625148-78-55
Capital Expenditures Incurred but Not yet Paid-----4----270
Buy-out of non-controlling interest----------1--
Right-of-use assets obtained in exchange for lease obligations--------31110--